Grant ID RP220416
Awarded On February 16, 2022
Title Therapeutic approaches for TGF-beta-enriched minimal residual disease in patients with colorectal cancer
Program Academic Research
Award Mechanism Individual Investigator
Institution/Organization The University of Texas M.D. Anderson Cancer Center
Principal Investigator/Program Director Van Morris
Cancer Sites Colorectal
Contracted Amount $1,050,000
Lay Summary

For patients with colorectal cancer treated with curative intention using surgery (with or without chemotherapy) microscopic areas of cancer may still remain and release their DNA into the bloodstream. When detected during a blood test, this circulating tumor DNA (ctDNA) can accurately forecast an eventual return of the cancer. Alternatively, if ctDNA is not detected, the colorectal cancer will likely not return. At this time, it is unknown if patients with detectable ctDNA benefit from receiving chemotherapy, or if small, incurable metastases which have already developed.

In this proposal, our team seeks to understand better the biology that uniquely defines these microscopic tumor depo...

Read More